Select Publications

Armstrong T et al. Chemotherapy-induced peripheral neuropathy. Oncol Nurs Forum 2005;32(2):305-11. Abstract

Berry DA et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295(14):1658-67. Abstract

Boehmke MM, Dickerson SS. The diagnosis of breast cancer: Transition from health to illness. Oncol Nurs Forum 2006;33(6):1121-7. Abstract

Bria E et al. Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: Pooled-analysis of 8794 patients. Cancer Treat Rev 2006;32(5):325-32. Abstract

Brufsky A. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: A Z-FAST update. Semin Oncol 2006;33(2 Suppl 7):13-7. Abstract

Buzdar AU, Cuzick J. Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: Emerging data. Clin Cancer Res 2006;12(3 Pt 2):1037s-48s. Abstract

Byar KL et al. Impact of adjuvant breast cancer chemotherapy on fatigue, other symptoms, and quality of life. Oncol Nurs Forum 2006;33(1):E18-26. Abstract

Carlson RW et al. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 2006;4(Suppl 3):1-22. Abstract

Chorn N. Accurate identification of HER2-positive patients is essential for superior outcomes with trastuzumab therapy. Oncol Nurs Forum 2006;33(2):265-72. Abstract

Cuzick J et al. Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen? Br J Cancer 2006;94(4):460-4. Abstract

Forbes JF. The use of early adjuvant aromatase inhibitor therapy: Contributions from the BIG 1-98 letrozole trial. Semin Oncol 2006;33(2 Suppl 7):2-7. Abstract

Gelmon K et al. The role of capecitabine in first-line treatment for patients with metastatic breast cancer. Oncologist 2006;11(Suppl 1):42-51. Abstract

Goldstein LJ. Controversies in adjuvant endocrine treatment of premenopausal women. Clin Breast Cancer 2006;6(Suppl 2):36-40. Abstract

Goss PE. Preventing relapse beyond 5 years: The MA.17 extended adjuvant trial. Semin Oncol 2006;33(2 Suppl 7):8-12. Abstract

Gradishar WJ. Albumin-bound paclitaxel: A next-generation taxane. Expert Opin Pharmacother 2006;7(8):1041-53. Abstract

Jackisch C. HER-2-positive metastatic breast cancer: Optimizing trastuzumab-based therapy. Oncologist 2006;11(Suppl 1):34-41. Abstract

Joensuu H et al; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354(8):809-20. Abstract

Jones SE et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006;24(34):5381-7. Abstract

Jones SE et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005;23(24):5542-51. Abstract

Heidrich SM et al. Symptoms, symptom beliefs, and quality of life of older breast cancer survivors: A comparative study. Oncol Nurs Forum 2006;33(2):315-22. Abstract

Howell A et al; ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract

Keller JS. Implementation of a prechemotherapy educational intervention for women newly diagnosed with breast cancer. Clin J Oncol Nurs 2006;10(1):57-60. Abstract

Limburg CE. Screening, prevention, detection, and treatment of cancer therapy–induced bone loss in patients with breast cancer. Oncol Nurs Forum 2007;34(1):55-63. No abstract available

Mann BS et al. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen. Clin Cancer Res 2005;11(16):5671-7. Abstract

Miller KD et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial conducted by the Eastern Cooperative Oncology Group (E2100). Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 3.

Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23(4):792-9. Abstract

Muss H et al. Toxicity of older and younger patients (pts) treated (Rx) with intensive adjuvant chemotherapy (Cx) for node-positive (N+) breast cancer (BC): The CALGB experience. Proc ASCO 2006;Abstract 559.

Paik S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24(23):3726-34. Abstract

Paik S et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351(27):2817-26. Abstract

Payne J et al. Biomarkers, fatigue, sleep, and depressive symptoms in women with breast cancer: A pilot study. Oncol Nurs Forum 2006;33(4):775-83. Abstract

Perez EA et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006;24(19):3032-8. Abstract

Piccart-Gebhart MJ et al; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER 2-positive breast cancer. N Engl J Med 2005;353(16):1659-72. Abstract

Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353(16):1673-84. Abstract

Saphner T et al. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996;14(10):2738-46. Abstract

Slamon D et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 1.

Sledge GW et al. The role of angiogenesis inhibition in the treatment of breast cancer. Clin Adv Hematol Oncol 2006;4 Suppl 21(10):1-12. Abstract

Sura W et al. Level of fatigue in women receiving dose-dense versus standard chemotherapy for breast cancer: A pilot study. Oncol Nurs Forum 2006;33(5):1015-21. Abstract

Table of Contents

Top of Page